and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

Other Events. On March 11, 2026, Lineage Cell Therapeutics, Inc. (the “Company”) filed with the U.S. Securities and Exchange Commission (the “SEC”) a prospectus supplement dated March 11, 2026 (the “Prospectus Supplement”) to the prospectus dated May 14, 2024 (the “Base Prospectus”) that forms a part of the Company’s shelf registration statement on Form S-3 (File No. 333-277758) filed by the Company with the SEC on March 7, 2024 and declared effective by the SEC on May 14, 2024 (the “Registra…

and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

Other Events. As previously reported, in December 2021, Lineage Cell Therapeutics, Inc. (“we,” “us,” “our,” the “Company,” or “Lineage”), entered into a collaboration and license agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. (the “Roche Agreement”) under which our lead cell therapy program known as OpRegen® (also known as RG6501) is being developed for the treatment of ocular disorders, including geographic atrophy (“GA”) secondary to age-related macular degeneration (“AMD”). O…

and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

Other Events. On August 22, 2025, Lineage and WDI entered into a research collaboration agreement (the “RCA”) to advance the preclinical development of Lineage’s auditory neuronal cell transplant program, ReSonance (ANPI), for the treatment of hearing loss (the “Project”). WDI will fund up to $12 million in research collaboration costs over the approximate three-year term of the RCA. The main objective of the RCA is for the parties to complete a preclinical phase achieving readiness to potent…

and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

Other Events. As previously reported, RG6501 (OpRegen®) is being evaluated in a Phase 1/2a clinical study in patients with GA secondary to AMD. OpRegen retinal pigment epithelium (RPE) cell therapy 36-month visual acuity results from patients enrolled in the study were presented at CTS 2025 on June 20, 2025. The presentation included that: • Improvement in visual acuity in Cohort 4 patients (patients with less advanced GA than in other cohorts) was present at 12 months (primary endpoint), 24…

Changes in Registrant’s Certifying Accountant. On June 3, 2025, Lineage Cell Therapeutics, Inc., (the “Company”) was notified that Moss Adams LLP (“Moss Adams”), the Company's independent registered public accounting firm, merged with Baker Tilly US, LLP (“Baker Tilly”), effective on June 3, 2025, and that the combined audit practices operate as Baker Tilly. In connection with the notification of the merger, Moss Adams resigned as the auditors of the Company and the Audit Committee of the Com…

and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

Other Events. In connection with the filing of the Prospectus Supplement, we are filing a legal opinion of our counsel, Sheppard, Mullin, Richter & Hampton LLP regarding the validity of the issuance and sale of the common shares, common warrants, placement agent warrants, and the common shares issuable upon exercise of the common warrants and placement agent warrants, which opinion is attached as Exhibit 5.1 to this report. Forward-Looking Statements This report contains forward-looking state…

Entry into a Material Definitive Agreement. On November 19, 2024, Lineage Cell Therapeutics, Inc. (“we,” “us,” “our,” or “Lineage”) entered into securities purchase agreements (collectively, the “securities purchase agreements”) with certain unaffiliated healthcare focused institutional investors and with Broadwood Partners, L.P. (“Broadwood”), an affiliate of Neal Bradsher, a member of our board of directors, relating to the purchase and sale in a registered direct offering of an aggregate o…

and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

Changes in Registrant’s Certifying Accountant. (a) Previous Independent Registered Public Accounting Firm On June 11, 2024, the Audit Committee of the Board of Directors of Lineage Cell Therapeutics, Inc. (the “Company”) approved the dismissal of WithumSmith+Brown, PC (“Withum”), as the Company’s independent registered public accounting firm, effective on that date. Withum audited the Company’s consolidated financial statements for the years ended December 31, 2023 and 2022. Withum’s report d…

Other Events. On May 14, 2024, Lineage Cell Therapeutics, Inc. (the “Company”) filed with the U.S. Securities and Exchange Commission (the “SEC”) a prospectus supplement dated May 14, 2024 (the “Prospectus Supplement”) to the prospectus dated May 14, 2024 (the “Prospectus”) that forms a part of the Company’s shelf registration statement on Form S-3 (File No. 333-277758) filed by the Company with the SEC on March 7, 2024 and declared effective by the SEC on May 14, 2024 (the “Registration Stat…

and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a fil…

Entry into a Material Definitive Agreement. On March 22, 2024, Lineage Cell Therapeutics, Inc. (the “Company” or “Lineage”), entered into a sales agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (the “Sales Agent”), under which the Company may offer and sell its common shares from time to time through the Sales Agent as the Company’s sales agent. Sales of the Company’s common shares through the Sales Agent, if any, will be made by any method permitted by law deemed to be an “a…

Other Events. Termination of Prior “At-the-Market” Offering Program and Offering Effective as of March 18, 2024, the Controlled Equity Offering Sales Agreement dated May 1, 2024 (the “Prior Sales Agreement”) between the Company and Cantor Fitzgerald & Co. (“Cantor”) was terminated pursuant to notice delivered by the Company to Cantor. The Company previously filed prospectus supplements (most recently on February 6, 2024) to the March 2021 Registration Statement (all such prospectus supplement…

and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a fil…

Entry into a Material Definitive Agreement. On February 6, 2024, Lineage Cell Therapeutics, Inc. (the “Company” or “Lineage”) entered into a stock purchase agreement (the “purchase agreement”) with certain investors relating to the purchase and sale in a registered direct offering of an aggregate of 13,461,540 common shares of the Company. The offering price was $1.04 per common share. The aggregate gross proceeds to Lineage from the offering are expected to be $14.0 million before deducting…

and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a fil…

and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a fil…